Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. RESULTS: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. CONCLUSIONS: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.19”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [19]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationManual of Clinical Laboratory Immunology
Rose, N. R., Hamilton, R. G., & Detrick, B. (1992) · Cited by 1,250
Cited by
Items 401–500 of 932
Kunacheewa, C., & Manasanch, E. E. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101152 · Cited by 15
“For example, a study of SMM indicated that the rate of progression to MM was 10% per year in first 5 years, 3% per year in the next 5 years, and 1% per year thereafter [2].”
BackgroundAllen, H. C., & Sharma, P. (2021) · StatPearls · Cited by 31
Maciocia, N., Wechalekar, A. D., & Yong, K. (2016) · Hematological Oncology · doi:10.1002/hon.2345 · Cited by 16
“8 years.(5) Patients with SMM lack evidence of end organ damage, but a small proportion may warrant treatment on the basis of high‐risk biomarkers.”
BackgroundDiagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia
Tedeschi, A., Conticello, C., Rizzi, R., Benevolo, G., Laurenti, L., Petrucci, M. T., Zaja, F. F., & Varettoni, M. (2018) · Hematological Oncology · doi:10.1002/hon.2539 · Cited by 16
MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1
Xu, K., Hu, X., Sun, L., Liang, Q., Ouyang, G., Zhang, Y., Mu, Q., & Yan, X. (2019) · Human Cell · doi:10.1007/s13577-019-00276-y · Cited by 13
Multiple Myeloma and Systemic Lupus Erythematosus in a Young Woman
Okoli, K., Irani, F., & Horvath, W. (2009) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181b0fe1e · Cited by 13
“The median age of 45 years at diagnosis of multiple myeloma in this series is much younger than the median age of 64 years for multiple myeloma in the general population.(14) The young age of our patient suggest that age should not preclude a work up for multiple myeloma in SLE patients.”
BackgroundSmoldering multiple myeloma: taking the narrow over the wide path?
Avet‐Loiseau, H., & Bahlis, N. J. (2024) · Blood · doi:10.1182/blood.2024023880 · Cited by 12
Óskarsson, J. Þ., Rögnvaldsson, S., Þorsteinsdóttir, S., Long, T. E., Ólafsson, A., Eyþórsson, E. S., Jónsson, Á., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01201-9 · Cited by 13
Samur, A. A., Corre, J., Talluri, S., Shah, P. S., Graffeuil, A., Rivera, J., Fan, Y., Dakiki, B., Szalat, R. E., Fulciniti, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00289 · Cited by 12
Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, L. K., Messersmith, H. J., Hadidi, S. S. A. A., Banerjee, R. K., Derman, B. A., Kumar, S. K., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02587 · Cited by 17
Muchtar, E., Kumar, S. K., Magen, H., & Gertz, M. A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1334124 · Cited by 13
“Its prevalence seems to correlate with tumor burden, with the lowest prevalence seen in MGUS (24–28% of patients) [28,29], 52–83% in SMM [6,30], 72% in AL amyloidosis [31], and as high as 91% in symptomatic MM [32].”
BackgroundResultInfluentialNetwork-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells
Ramakrishnan, V., & Mager, D. E. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.247924 · Cited by 14
“The risk of progression from monoclonal gammopathy of undetermined significance to SM, and SM to myeloma is approximately 1% and 10% per year (Kyle et al., 2007; Landgren et al., 2009).”
BackgroundRisk Stratification and Treatment in Smoldering Multiple Myeloma
Lussier, T., Schoebe, N., & Mai, S. (2021) · Cells · doi:10.3390/cells11010130 · Cited by 12
“Note that the same classification is not necessarily equivalent between models (e.g., high-risk in Kyle et al. (2007)’s model [10] is not necessarily equivalent to high risk in Pérez-Persona’s model [12]).”
BackgroundMethodInfluentialIskrzak, J., Zygmunciak, P., Misiewicz-Krzemińska, I., & Puła, B. (2022) · Cancers · doi:10.3390/cancers14225575 · Cited by 13
“ECs—endothelial cells, EC-EVs—endothelial cell-derived extracellular vesicles, FIH1—factor-inhibiting hypoxia-inducible factor 1, IL-1β—interleukin 1β, IL-3—interleukin 3, IL-6—interleukin 6, IL-8—interleukin 8, IL10—interleukin 10, MGUS—monoclonal gammopathy of undetermined significance, miR-126— microRNA-126, MM—mul…”
BackgroundInfluentialMellgard, G. S., Gilligan, M. M., Cliff, E. R. S., Bhutani, D., Mohyuddin, G. R., Eisenberger, A. B., Lentzsch, S., & Chakraborty, R. (2024) · HemaSphere · doi:10.1002/hem3.61 · Cited by 13
“Baseline demographics and clinical characteristics of the cohort are shown in Appendix SI, which also includes clinical characteristics of patients with SMM from the Olmsted County study 3 and a contemporary screening ‐ detected cohort from the iStopMM study for comparison.”
MethodTreatment of smoldering multiple myeloma
Rajkumar, S. V., & Kyle, R. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.160 · Cited by 12
Self-citationEmerging Strategies for Targeting Cell Adhesion in Multiple Myeloma
Nair, R. R., Gebhard, A. W., Emmons, M. F., & Hazlehurst, L. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00006-3 · Cited by 12
Wennmann, M., Hielscher, T., Kintzelé, L., Menze, B. H., Langs, G., Merz, M., Sauer, S., Kauczor, H., Schlemmer, H., Delorme, S., et al. (2021) · Cancers · doi:10.3390/cancers13050961 · Cited by 12
“Finally, even within a single stage, time to progression various enormously; in SMM, 20% of patients become symptomatic within 2 years, while one third does not progress to MM within a decade [4].”
BackgroundSmoldering multiple myeloma – Past, present, and future
Mann, H., Katiyar, V., Varga, C., & Comenzo, R. L. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100869 · Cited by 12
Jin, Y., Savage, N. M., Bollag, R. J., Xu, H., & Singh, G. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab090 · Cited by 12
Lonial, S., Rajkumar, S. V., & Mateos, M. V. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00335-5 · Cited by 9
Self-citationStella, F., Pedrazzini, E., Baialardo, E. M., Fantl, D. B. E., Schutz, N. P., & Slavutsky, I. R. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.05.006 · Cited by 12
Yusuf, A., Natwick, T., Werther, W., Felici, D., Mahue, M., Bridges, K. R., & Peng, Y. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1226166 · Cited by 13
“We excluded (1) patients with a multiple myeloma diagnosis in the 12 months before the disease index date and (2) patients with evidence of chemotherapy, radiotherapy, or stem cell transplantation in the 6 months before the disease index date.”
MethodA phase II trial of TBL ‐12 sea cucumber extract in patients with untreated asymptomatic myeloma
Chari, A., Mazumder, A., Lau, K., Catamero, D., Galitzeck, Z., & Jagannath, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14314 · Cited by 12
Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies
Seppänen, M. R. J. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12493 · Cited by 12
Targeted therapy of multiple myeloma
Kyle, R. A. (2012) · Hematology · doi:10.1179/102453312x13336169156339 · Cited by 14
Self-citationQuach, H., Joshua, D., Ho, J., Szer, J., Spencer, A. G., Harrison, S. J., Mollee, P. N., Roberts, A. W., Horvath, N., Talaulikar, D., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12688 · Cited by 13
Medina-Herrera, A., Vazquez, I., Cuenca, I., Rosa-Rosa, J. M., Ariceta, B., Jimenez, C., Fernandez-Mercado, M., Larrayoz, M. J., Gutierrez, N. C., Fernandez-Guijarro, M., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01053-3 · Cited by 11
Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021
Kysenius, K., Anttalainen, A., Toppila, I., Miettinen, T. A., Lassenius, M. I., Lievonen, J., Partanen, A., Silvennoinen, R. H., & Putkonen, M. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05865-y · Cited by 12
“MM develops from an asymptomatic premalignant state known as MGUS (monoclonal gammopathy of unknown significance) and/or asymptomatic MM (smoldering MM, SMM) to the malignant disease [23, 24].”
BackgroundHow is patient care for multiple myeloma advancing?
Stavric, S. G., Bonello, F., Bringhen, S., Boccadoro, M., & Larocca, A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1326814 · Cited by 12
Primary Bone Tumors in North of Jordan
Bashaireh, K. M., Alorjani, M. S., Jahmani, R. A., Khateeb, A. A., Nimri, F., Al-Ebbini, M. A., & Ababneh, A. R. M. (2020) · Journal of Epidemiology and Global Health · doi:10.2991/jegh.k.201102.001 · Cited by 11
“Immediate management depends on the presence of symptoms, because studies revealed that early treatment without symptoms has no benefits [29,30].”
Screening in Multiple Myeloma and Its Precursors: Are We There Yet?
Rögnvaldsson, S., Þorsteinsdóttir, S., & Kristinsson, S. Y. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad148 · Cited by 12
Gong, L., Qiu, L., & Hao, M. (2024) · Cancers · doi:10.3390/cancers16030498 · Cited by 11
“The cumulative probability of progression will reach 73% at 15 years [2].”
BackgroundNovel treatment paradigm for elderly patients with multiple myeloma.
Palumbo, A. P., & Magarotto, V. (2011) · PubMed · Cited by 11
Evolving Paradigms in the Treatment of Newly Diagnosed Multiple Myeloma
Larocca, A., & Palumbo, A. P. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0096 · Cited by 11
Nuances in the Management of Older People With Multiple Myeloma
Pawlyn, C., Gay, F., Larocca, A., Roy, V., & Ailawadhi, S. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0323-4 · Cited by 11
Jean‐Baptiste, M., Gries, K. S., Lenderking, W. R., & Fastenau, J. M. (2020) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00253-2 · Cited by 11
Li, J., Tan, H., Xu, T., Shi, H., & Liu, P. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04629-2 · Cited by 12
The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias
Jasiński, M., Biliński, J., & Basak, G. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741376 · Cited by 11
“Smouldering MM (SMM) is an asymptomatic, intermediate stage between MGUS and MM, that carries a 10% risk of progression to symptomatic MM per year during the first five years after diagnosis (4).”
BackgroundMyelomagenesis: Capturing Early Microenvironment Changes
Korde, N., & Marić, I. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.11.004 · Cited by 14
Monoclonal gammopathy and rheumatic diseases.
Raposo, A., Peixoto, D., & Bogas, M. (2014) · PubMed · Cited by 11
Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma
Ruiz‐Heredia, Y., Ortiz-Ruiz, A., Samur, M., Garrido, V., Rufián, L., Sánchez, R., Aguilar-Garrido, P., Barrio, S., Martín, M. A., Bolli, N., et al. (2021) · Cancers · doi:10.3390/cancers13133189 · Cited by 11
“Several different models have been tested for predicting progression to active MM— including the Mayo Clinic model, the PETHEMA model and the 20-20-20 model [17]—and novel imaging technologies, such as PET-CT [18], can complement more traditional approaches like fluorescent in situ hybridization and peripheral blood p…”
MethodMONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND SMOLDERING MULTIPLE MYELOMA
Kyle, R. A., & Rajkumar, S. V. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511551901.013 · Cited by 11
Self-citationPuig, N., Agulló, C., Contreras, T., Pérez, J.-J., Aires‐Mejía, I., Calasanz, M. J., García‐Sánz, R., Castro, S., Martínez‐López, J., Rodríguez‐Otero, P., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285742 · Cited by 14
Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential
Jordan, M. A., Morschl, J., & Autenrieth, S. E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1575509 · Cited by 12
“MGUS has <10% clonal plasma cells in the BM with a 1% annual progression risk (2), while SMM has >10% clonal plasma cells and a 10% annual progression risk (3).”
Zhou, Y., Nair, B. P., Shaughnessy, J. D., Cartron, M.-A., Haessler, J., Anaissie, E. J., van Rhee, F., Crowley, J. J., & Barlogie, B. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07670.x · Cited by 10
“…lesion bone marrow samples and associated with high-risk gene expression profile The presence of osteolytic lesions distinguishes multiple myeloma (MM) from its precursor condition, monoclonal gammopathy of undetermined significance (MGUS), and is the cause of major morbidity (Kyle et al, 2007).”
BackgroundAsymptomatic Monoclonal Gammopathies
Bories, C., & Jagannath, S. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.05.004 · Cited by 10
Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment
Nassar, S., Taher, A., Spear, R., Wang, F., Madewell, J. E., & Mujtaba, B. (2020) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2020.08.019 · Cited by 10
Hughes, D., Yong, K., Ramasamy, K., Stern, S., Boyle, E. M., Ashcroft, J., Basheer, F., Rabin, N. K., & Pratt, G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19333 · Cited by 10
The road to cure in multiple myeloma starts with smoldering disease
Salem, K. Z., & Ghobrial, I. M. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1036740 · Cited by 10
“The overall risk of progression of SMM is 10% per year for the first 5 years and 3% per year for the next 5 years [26].”
BackgroundInfluentialDevelopment of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future
Landgren, O., & Rajkumar, S. V. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.11.009 · Cited by 10
“Future goals should be (1) to provide molecularly based predictions of transformation from MGUS/SMM to multiple myeloma; (2) to use molecular markers to counsel patients with regard to future clinical follow-up/intervention; and (3) to develop novel treatments for patients with high-risk multiple myeloma precursor dis…”
BackgroundSelf-citationSmoldering Multiple Myeloma: Emerging Concepts and Therapeutics
Sundararajan, S., Kumar, A., Korde, N., & Agarwal, A. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0305-6 · Cited by 11
What Is New in the Treatment of Smoldering Multiple Myeloma?
Bolli, N., Sgherza, N., Curci, P., Rizzi, R., Strafella, V., Delia, M., Gagliardi, V. P., Neri, A., Baldini, L., Albano, F., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030421 · Cited by 10
“In the continuous spectrum of monoclonal gammopathies, smoldering multiple myeloma (SMM) occupies an intermediate position between what is usually referred to as a pre-malignant condition, i.e., monoclonal gammopathy of indeterminate significance (MGUS) and active multiple myeloma.”
BackgroundResultInfluentialWhen a Monoclonal Gammopathy Is Not Multiple Myeloma
Derman, B. A., Castillo, J. J., Sarosiek, S., & Beksaç, M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349643 · Cited by 27
Cao, Y.-J., Zheng, Y.-H., Li, Q., Zheng, J., Ma, L.-T., Zhao, C.-J., & Li, T. (2022) · Journal of Oncology · doi:10.1155/2022/4705654 · Cited by 10
“[4].”
Emery, A., Moore, S. E., Crowe, J., Murray, J., Peacock, O., Thompson, D., Betts, F., Rapps, S., Ross, L., Rothschild-Rodriguez, D., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11817-6 · Cited by 10
The prognostic value of TIMP-1 in multiple myeloma
Guédez, L., & Stetler‐Stevenson, W. G. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.10.005 · Cited by 10
“Moreover, recent clinical and experimental data reveal that lytic bone disease is key for MM progression [7,8].”
BackgroundTete, S. M., Kipling, D., Westra, J., de Haan, A., Bijl, M., Dunn‐Walters, D. K., Sahota, S. S., & Bos, N. A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.02.005 · Cited by 10
“The condition is associated with hypogammaglobulinaemia in 20%–28% of cases [10–12], which may reflect an impact of the monoclonal clone on normal plasma cells in the bone marrow niche.”
BackgroundRole of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma
Olteanu, H. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2015.09.009 · Cited by 11
Eckold, J., Poenisch, W., Drogies, T., Kratzsch, J., Teupser, D., Thiery, J., & Bruegel, M. (2014) · Clinical Laboratory · doi:10.7754/clin.lab.2013.131010 · Cited by 10
Lipe, B. C., Kambhampati, S., Veldhuizen, P. J. V., Yacoub, A., Aljitawi, O. S., & Mikhael, J. R. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0015-x · Cited by 10
Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma
Kumar, S. K., Glazebrook, K. N., & Broski, S. M. (2019) · PET Clinics · doi:10.1016/j.cpet.2019.03.006 · Cited by 10
Clinical Controversies in the Management of Smoldering Multiple Myeloma
Lomas, O., & Ghobrial, I. M. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_278911 · Cited by 11
Kyle, R. A., & Dispenzieri, A. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7234-3691-1.00094-5 · Cited by 10
Self-citationLandgren, O., & Korde, N. (2011) · PubMed · Cited by 11
Pontikoglou, C. G., Filippatos, T. D., Matheakakis, A., & Papadaki, H. Α. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156000 · Cited by 9
Vu, T., Wang, Y., Fowler, A., Simieou, A., & McCarty, N. (2024) · Cells · doi:10.3390/cells13171431 · Cited by 9
“Patients with SMM have an annual progression rate of 10%, in contrast to 1% in MGUS patients [23,24].”
BackgroundCellular Therapies for Multiple Myeloma: Engineering Hope
Vera-Cruz, S., Culubret, M., Konetzki, V., Alb, M., Friedel, S. R., Hudecek, M., Einsele, H., Danhof, S., & Scheller, L. (2024) · Cancers · doi:10.3390/cancers16223867 · Cited by 9
“MM typically evolves from pre-malignant conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM) [3].”
Recurrent Cytogenetic Abnormalities in Multiple Myeloma
Chan, N. C. N., & Chan, N. P. H. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6703-2_23 · Cited by 9
Multiple myeloma – 2020 update on diagnosis and management
Charliński, G., & Jurczyszyn, A. J. (2020) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2020.0035 · Cited by 10
“Approximately 73% of SMM patients will progress to MM within 15 years [8].”
BackgroundmiRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance
Pirzaman, A. T., Ebrahimi, P., Hasanpour, A., Shakeri, M., Babajani, B., Ganji, Z. P., Babaei, H., Rahmati, A., Hosseinzadeh, R., Doostmohamadian, S., et al. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231202391 · Cited by 11
“Ten percent of SMM patients acquire MM during the first five years of diagnosis; after that, the risk of progression falls.(17) The exact causes and risk factors contributing to the development of MM remain to be fully elucidated.”
BackgroundDNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma
Neeli, P. K., Maza, P. A. M., Chai, D., Zhao, D., Hoi, X. P., Chan, K. S., Young, K. H., & Li, Y. (2024) · npj Vaccines · doi:10.1038/s41541-024-00979-w · Cited by 9
Karathanasis, N., & Spyrou, G. M. (2025) · Cancers · doi:10.3390/cancers17020332 · Cited by 10
“In particular cases, an intermediate asymptomatic but more advanced pre-malignant stage, termed smoldering multiple myeloma (SMM), may be clinically recognizable [16].”
Smoldering Multiple Myeloma: When to Observe and When to Treat?
Mateos, M., & Miguel, J. F. S. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e484 · Cited by 11
Challenges in multiple myeloma diagnosis and treatment
Girnius, S. K., & Munshi, N. C. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.2 · Cited by 10
Okura, T., Miyoshi, K., Nagao, T., Jotoku, M., Enomoto, D., Irita, J., Kurata, M., & Higaki, J. (2009) · Internal Medicine · doi:10.2169/internalmedicine.48.1679 · Cited by 9
“MGUS is characterized by a serum monoclonal protein level of less than 3 g/dL, a proportion of plasma cells in the bone marrow that is less than 10% (9).”
BackgroundClinical trials of bisphosphonates in multiple myeloma.
Mahindra, A. K., Pozzi, S., & Raje, N. S. (2012) · PubMed · Cited by 9
Yi, Z., Ma, T., Liu, J., Tie, W., Li, Y., Bai, J. Y., Li, L., & Zhang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925266 · Cited by 9
“Thus, approximately 1% of patients with MGUS and 10% of patients with SMM will develop active MM every year (17, 18).”
BackgroundIncreased Expression of SRSF1 Predicts Poor Prognosis in Multiple Myeloma
Zhang, J., Wang, Z., Wang, K., Xin, D., Wang, L., Fan, Y., & Xu, Y. (2023) · Journal of Oncology · doi:10.1155/2023/9998927 · Cited by 10
“Between MGUS and MM, smoldering multiple myeloma (SMM) represents an intermediate, asymptomatic condition without the SLiM features, which stand for sixty, light chain ratio, MRI, but at a higher risk of progression to MM [4].”
Strategy for Detecting and Following Monoclonal Gammopathies
Katzmann, J. A., & Keren, D. F. (2016) · ASM Press eBooks · doi:10.1128/9781555818722.ch11 · Cited by 9
Campbell, J. P., Heaney, J. L. J., Pandya, S., Afzal, Z., Kaiser, M., Owen, R. G., Child, J. A., Cairns, D. A., Gregory, W. M., Morgan, G. J., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30209-0 · Cited by 10
“Smouldering multiple myeloma (SMM) – an intermediate disease stage between MGUS and MM – has a 10% risk of MM progression each year initially but therapy is not recommended because studies of intervention with conventional chemotherapy have shown little benefit (11).”
BackgroundLehners, N., Ellert, E., Xu, J., Hillengaß, J., Leichsenring, J., Stenzinger, A., Goldschmidt, H., Andrulis, M., & Raab, M. S. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1443450 · Cited by 9
“or high-risk cytogenetics [2,23,25], the pathogenic”
BackgroundZhang, L., Liu, D., Tang, B., Xu, A., Huang, H., Yan, S., Xu, J., Deng, J., Tang, L. V., Sun, C., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9245 · Cited by 9
The Evolution of Monoclonal Gammopathy of Undetermined Significance in Kidney Transplant Recipients
Gagnon, M.-F., Cardinal, H., Émond, J.-P., Latour, M., & Lemieux, B. (2019) · Transplantation Direct · doi:10.1097/txd.0000000000000937 · Cited by 10
Santoni, G., Amantini, C., Maggi, F., Marinelli, O., Santoni, M., & Morelli, M. B. (2022) · Biomolecules · doi:10.3390/biom12010107 · Cited by 9
“MM evolves from a pre-malignant stage monoclonal gammopathy of undetermined significance (MGUS) [4,5] and an asymptomatic intermediate stage called smoldering multiple myeloma (SMM) [6,7].”
BackgroundTreatment of Multiple Myeloma: A Comprehensive Review
Kyle, R. A., & Rajkumar, S. V. (2009) · Clinical Cancer Reviews · doi:10.3816/ccr.2009.n.008 · Cited by 9
Self-citation18F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma
Hemrom, A., Tupalli, A., Alavi, A. A., & Kumar, R. (2022) · PET Clinics · doi:10.1016/j.cpet.2022.03.001 · Cited by 9
The Current Status and Future of Multiple Myeloma in the Clinic
Jagannath, S., Kyle, R. A., Palumbo, A. P., Siegel, D. S. D., Cunningham, S. A., & Berenson, J. R. (2009) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clm.2010.n.005 · Cited by 10
Self-citationPlasma Cell Neoplasms, Their Precursor States, and Their Prediction of Organ Damage
Comenzo, R. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2892 · Cited by 9
“Monoclonal gammopathies are common, but the challenge is to determine whether they are passengers that are linked to putative immune or autoimmune dysregulation, or true drivers of disease or, as sometime happens, both.(13,14) The symptoms of”
BackgroundMultiple Myeloma: Risk Factors, Pathogenesis and Relationship with Anti-myeloma Therapies
Nwabuko, O. C. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2022.00059 · Cited by 9
Tang, G., Wu, Y., Lin, P., Törüner, G., Hu, S., Li, S., Qazilbash, M. H., Orlowski, R. Z., Ye, C., Xu, J., et al. (2023) · Cancers · doi:10.3390/cancers15235690 · Cited by 8
“In some patients, an intermediate and asymptomatic but more advanced stage termed smoldering multiple myeloma (SMM) can be recognized [4].”
BackgroundInfluentialSmith, B., Li, Y., Fields, T., Tucker, M., Staskiewicz, A., Wong, E. C., Ma, H., Mao, H. Z., & Wang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1325196 · Cited by 10
“Although the underlying disease biology remains not fully elucidated (Kumar et al., 2017), an increasing body of evidence has suggested that MM is not a single disease but rather a collection of diseases with common clinical manifestations (Kyle et al., 2007).”
BackgroundSchmidt, T. M., Gahvari, Z. J., & Callander, N. S. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.008 · Cited by 8
Rueda, L. Y. M., Wang, H., Akagi, K., Dang, M., Vora, A. U., Qin, L., Lee, H. C., Patel, K. K., Lin, P., Mery, D. E., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101925 · Cited by 9
“…R 2 odd-numbered chromosome, 2 while the second includes immunoglobulin heavy-chain ( IGH ) locus translocations juxtaposing the IGH enhancer with cyclin D1 ( CCND1 ) [t(11;14)], nuclear receptor-binding SET domain protein-2 ( NSD2 ) [t(4;14)], or MAF bZIP transcription factor ( MAF ) [t(14;16)].”
Multiples Myelom: Aktuelle Empfehlungen für die Bildgebung
Hillengaß, J., & Delorme, S. (2012) · Der Radiologe · doi:10.1007/s00117-011-2257-0 · Cited by 8
Recommendations for Use of Free Light Chain Assay in Monoclonal Gammopathies
Radović, V. (2009) · Journal of Medical Biochemistry · doi:10.2478/v10011-009-0034-7 · Cited by 8
“In addition to the use of FLC for prognosis in MGUS, baseline rFLC is useful for assessing prog nosis for progression in smoldering MM (24).”
MethodBhutani, M., & Landgren, O. (2014) · Der Radiologe · doi:10.1007/s00117-014-2694-7 · Cited by 8
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00104-1 · Cited by 9
Self-citationChojnacka, M., Diamond, B. T., Landgren, O., & Maura, F. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.006 · Cited by 8
Sandecká, V., Popková, T., Štork, M., Maisnar, V., Minařík, J., Jungová, A., Pavlíček, P., Stejskal, L., Pospíšilová, L., Heindorfer, A., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00906-7 · Cited by 8
“The risk for progression in patients with SMM has been estimated to be 73% over 15 years and to be greatest in the fi rst few years following diagnosis: 10% per year over the fi rst 5 years, 3% per year for the next 5 years, and 1% per year for the following 10 years [7].”
Influential
Metadata
- Authors
- Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2582-2590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974983065
- Cited by
- 921
- References
- 25
- Citations by year
- 2026: 34 · 2025: 57 · 2024: 62 · 2023: 48 · 2022: 56 · 2021: 69 · 2020: 70 · 2019: 45 · 2018: 49 · 2017: 37 · 2016: 55 · 2015: 46 · 2014: 50 · 2013: 56 · 2012: 42
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 107 476, CA6 2242, R01CA107476, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, asymptomatic multiple myeloma, amyloidosis, prognostic factors, risk stratification, clinical course
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amyloidosis, Antibodies, Monoclonal, Biopsy, Bone Marrow Cells, Bone Marrow Examination, Female, Humans, Male, Middle Aged, Multiple Myeloma, Plasma Cells, Prognosis, Risk Factors, Cohort Studies, Disease Progression, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.